Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antihypertensive drug therapy in older patients
Autore:
Wang, JG; Staessen, JA;
Indirizzi:
Univ Leuven, Dept Mol & Cardiovasc Res, Hypertens & Cardiovasc Rehabil Unit, Louvain, Belgium Univ Leuven Louvain Belgium & Cardiovasc Rehabil Unit, Louvain, Belgium
Titolo Testata:
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
fascicolo: 2, volume: 10, anno: 2001,
pagine: 263 - 269
SICI:
1062-4821(200103)10:2<263:ADTIOP>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
ISOLATED SYSTOLIC HYPERTENSION; CORONARY HEART-DISEASE; CONVERTING-ENZYME-INHIBITION; BLOOD-PRESSURE; RANDOMIZED TRIAL; PULSE PRESSURE; CARDIOVASCULAR MORTALITY; MYOCARDIAL-INFARCTION; ELDERLY PATIENTS; ACTIVE TREATMENT;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
56
Recensione:
Indirizzi per estratti:
Indirizzo: Staessen, JA Katholieke Univ Leuven, Lab Hypertensie, Studiecoordinatiecent, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium Katholieke Univ Leuven Campus Gasthuisberg,Herestr 49 Louvain Belgium B-3000
Citazione:
J.G. Wang e J.A. Staessen, "Antihypertensive drug therapy in older patients", CURR OP NEP, 10(2), 2001, pp. 263-269

Abstract

Elevated pulse pressure is an important cardiovascular risk factor in the elderly, and it remains to be determined whether this can be reversed. Drugtreatment is justified in older patients with isolated systolic hypertension whose systolic blood pressure is 160 mmHg or higher on repeated measurement. Absolute benefit is greater in men, in patients aged 70 years or more,and in those with previous cardiovascular complications or greater pulse pressure. In the recently published comparative trials blood pressure gradients largely accounted for most, if not all, of the differences in outcome. In hypertensive patients, calcium-channel blockers may offer greater protection against stroke than against myocardial infarction, resulting in an overall cardiovascular benefit similar to that provided by older drug classes. The hypothesis that angiotensin-converting enzyme inhibitors or a-blockersmight influence outcome over and beyond that expected on the basis of their blood pressure lowering effects still remains to be proved. Curr Opin Nephrol Hypertens 10:263-269. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 03:39:02